Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts

Lisa Nocquet,Julie Roul,Chloé C. Lefebvre,Laurine Duarte,Mario Campone,Philippe P. Juin,Frédérique Souazé

DOI: https://doi.org/10.1038/s41598-024-64696-z

IF: 4.6

2024-06-21

Scientific Reports

Abstract:Triple negative breast cancers (TNBC) present a poor prognosis primarily due to their resistance to chemotherapy. This resistance is known to be associated with elevated expression of certain anti-apoptotic members within the proteins of the BCL-2 family (namely BCL-xL, MCL-1 and BCL-2). These regulate cell death by inhibiting pro-apoptotic protein activation through binding and sequestration and they can be selectively antagonized by BH3 mimetics. Yet the individual influences of BCL-xL, MCL-1, and BCL-2 on the sensitivity of TNBC cells to chemotherapy, and their regulation by cancer-associated fibroblasts (CAFs), major components of the tumor stroma and key contributors to therapy resistance remain to be delineated. Using gene editing or BH3 mimetics to inhibit anti-apoptotic BCL-2 family proteins in TNBC line MDA-MB-231, we show that BCL-xL and MCL-1 promote cancer cell survival through compensatory mechanisms. This cell line shows limited sensitivity to chemotherapy, in line with the clinical resistance observed in TNBC patients. We elucidate that BCL-xL plays a pivotal role in therapy response, as its depletion or pharmacological inhibition heightened chemotherapy effectiveness. Moreover, BCL-xL expression is associated with chemotherapy resistance in patient-derived tumoroids where its pharmacological inhibition enhances ex vivo response to chemotherapy. In a co-culture model of cancer cells and CAFs, we observe that even in a context where BCL-xL reduced expression renders cancer cells more susceptible to chemotherapy, those in contact with CAFs display reduced sensitivity to chemotherapy. Thus CAFs exert a profound pro-survival effect in breast cancer cells, even in a setting highly favoring cell death through combined chemotherapy and absence of the main actor of chemoresistance, BCL-xL.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the resistance of triple - negative breast cancer (TNBC) to chemotherapy drugs. Specifically, the researchers are concerned with how the expression of BCL - xL, an anti - apoptotic protein, in TNBC cells affects the efficacy of chemotherapy, and how cancer - associated fibroblasts (CAFs) limit the efficacy of chemotherapy through their interaction with cancer cells.

### Main research contents:

1. **Roles of BCL - xL and MCL - 1 in TNBC cells**:
- The researchers used CRISPR - Cas9 gene editing and BH3 mimetics (a small - molecule compound that can inhibit anti - apoptotic proteins of the BCL - 2 family) to explore the roles of BCL - xL and MCL - 1 in the MDA - MB - 231 cell line.
- The results showed that BCL - xL and MCL - 1 play crucial roles in promoting the survival of TNBC cells, and there is a compensation mechanism between these two proteins. Inhibiting BCL - xL or MCL - 1 alone is not sufficient to cause large - scale apoptosis, but inhibiting both simultaneously can significantly increase apoptosis.

2. **Effect of BCL - xL on the efficacy of chemotherapy**:
- The researchers found that the expression level of BCL - xL is negatively correlated with the sensitivity of TNBC cells to chemotherapy. Cells with low BCL - xL expression are more sensitive to chemotherapy, while cells with high BCL - xL expression show stronger resistance.
- By gene silencing or drug - inhibiting BCL - xL, the sensitivity of MDA - MB - 231 cells to chemotherapy can be significantly improved, even reaching a nearly 100% cell death rate.

3. **Effect of CAFs on the efficacy of chemotherapy**:
- The researchers found in a co - culture model that even when BCL - xL expression is reduced, CAFs can still protect TNBC cells from the effects of chemotherapy.
- CAFs enhance the survival ability of cancer cells by secreting various factors (such as growth factors, cytokines, and matrix components), thereby reducing the effectiveness of chemotherapy.

### Conclusions:

- **BCL - xL is a key factor in TNBC cells' resistance to chemotherapy**: Inhibiting BCL - xL can significantly improve the sensitivity of TNBC cells to chemotherapy.
- **The important role of CAFs in chemotherapy resistance**: Even when BCL - xL is inhibited, CAFs can still protect cancer cells through multiple mechanisms, leading to a decrease in the efficacy of chemotherapy.
- **Suggestions for future treatment strategies**: In order to improve the chemotherapy efficacy of TNBC, new treatment strategies need to be developed by simultaneously targeting the action mechanisms of BCL - xL and CAFs.

### Explanation of formulas and symbols:

- **BCL - xL**: B - cell lymphoma - extra large, an anti - apoptotic protein.
- **MCL - 1**: Myeloid cell leukemia 1, another anti - apoptotic protein.
- **BH3 mimetics**: A class of small - molecule compounds that can inhibit the activity of anti - apoptotic proteins of the BCL - 2 family.
- **CAFs**: Cancer - associated fibroblasts.
- **MDA - MB - 231**: A commonly used TNBC cell line.
- **Chemotherapy drugs**: Such as Doxorubicin, Cisplatin, and 5 - Fluorouracil.

Hope this information is helpful for you to understand this paper! If you have more questions, feel free to continue asking.